Quadrant Capital Group LLC Sells 651 Shares of Hologic, Inc. (NASDAQ:HOLX)

Quadrant Capital Group LLC reduced its position in Hologic, Inc. (NASDAQ:HOLX) by 30.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 1,467 shares of the medical equipment provider’s stock after selling 651 shares during the period. Quadrant Capital Group LLC’s holdings in Hologic were worth $106,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in HOLX. Resona Asset Management Co. Ltd. bought a new stake in shares of Hologic in the 4th quarter valued at about $6,090,000. Prudential PLC lifted its holdings in Hologic by 4.5% during the fourth quarter. Prudential PLC now owns 87,841 shares of the medical equipment provider’s stock worth $6,332,000 after buying an additional 3,819 shares during the period. Westpac Banking Corp boosted its position in Hologic by 24.9% during the 4th quarter. Westpac Banking Corp now owns 41,173 shares of the medical equipment provider’s stock valued at $2,968,000 after acquiring an additional 8,200 shares in the last quarter. Bryce Point Capital LLC purchased a new position in shares of Hologic in the 4th quarter valued at $488,000. Finally, Massachusetts Financial Services Co. MA raised its position in shares of Hologic by 56.6% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 44,291 shares of the medical equipment provider’s stock worth $3,193,000 after acquiring an additional 16,012 shares in the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. William Blair reaffirmed an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Needham & Company LLC downgraded Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target on the stock. in a research report on Monday, February 3rd. Citigroup lowered their price objective on Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Raymond James reaffirmed an “outperform” rating and set a $90.00 target price (down from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Finally, Morgan Stanley lowered their price target on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $84.62.

Hologic Price Performance

Shares of NASDAQ HOLX opened at $59.31 on Thursday. The firm has a 50-day simple moving average of $63.03 and a 200-day simple moving average of $71.87. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $13.31 billion, a price-to-earnings ratio of 18.71, a price-to-earnings-growth ratio of 2.14 and a beta of 0.82. Hologic, Inc. has a 52 week low of $57.38 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, equities analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.